Literature DB >> 12473467

An evaluation of the efficacy of Aqualox for microbiological control of industrial cooling tower systems.

E L Prince1, A V G Muir, W M Thomas, R J Stollard, M Sampson, J A Lewis.   

Abstract

A comprehensive sampling protocol was employed to evaluate the efficacy of Aqualox, a biocide based on electrochemically activated water, against legionellae and heterotrophic bacteria in two industrial cooling tower systems. Both of the towers in the study remained free from evidence of Legionella spp. contamination throughout a five-month evaluation period, despite the previously demonstrated presence of legionellae in one of the test towers, and in two other towers on the same site, at levels well in excess of UK Health and Safety Commission (HSC) Approved Code of Practice and Guidance (ACOP) upper action limits. Levels of heterotrophic bacteria were controlled below 10(4) cfu/mL in both towers throughout most of the trial. Results also provided indirect evidence of significant activity against biofilm bacteria, with biofilm removal beginning almost immediately after commissioning of the Aqualox treatment systems. The results were particularly encouraging as the two towers studied had a long history of poor microbiological control using conventional bromine-based biocide products. Significant differences were observed between laboratory measurements of total viable counts on frequent liquid samples and those obtained from dip slides following HSC recommendations. Copyright 2002 The Hospital Infection Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473467     DOI: 10.1053/jhin.2002.1293

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  1 in total

Review 1.  Electrochemically activated solutions: evidence for antimicrobial efficacy and applications in healthcare environments.

Authors:  R M S Thorn; S W H Lee; G M Robinson; J Greenman; D M Reynolds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-02       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.